In a recent issue of Intensive Care Medicine, Bassetti and colleagues [1] evaluated 216 patients with septic shock attributable to Candida bloodstream infection from five teaching hospitals in Italy and Spain. Overall, 116 patients (53.7 %) died within 30 days from the onset of Candida bloodstream infection. Multivariate logistic regression analysis demonstrated that inadequate source control, inadequate antifungal therapy, and increasing severity of illness measured by APACHE II scores were independently associated with greater 30-day mortality. Initial treatment was considered adequate if the infecting organism was susceptible to the prescribed antimicrobial regimen and the dosage of antifungal used was adequate within the first 24 h from culture positivity.
The results of this study confirm the findings of Kollef et al.
[2] who identified 224 consecutive patients with septic shock and a positive blood culture for Candida from St. Louis, Missouri. Overall hospital mortality occurred among 155 (63.5 %) patients. Similar to the study above, multivariate logistic regression analysis demonstrated that delayed antifungal treatment and failure to achieve timely source control were independently associated with a greater risk of hospital mortality. Antimicrobial treatment was classified as adequate if the prescribed antibiotic regimen included an antifungal agent directed against the isolated Candida species and was administered within 24 h of the onset of septic shock. Despite differences in the definition employed for adequate antifungal therapy, these studies, like others [3-5], emphasize the importance of timely treatment with antifungal agents and source control in Candida septic shock in order to optimize patient outcomes.
It is also important to note that several recent investigations were unable to identify a beneficial association between the timing of antifungal therapy and mortality in patients with Candida bloodstream infection [6, 7] . This could be explained by the reported greater clinical efficacy of echinocandins in this setting as compared with fluconazole, potentially minimizing the deleterious effect of delayed therapy [8] . However the rationale in favor of early adequate antifungal therapy seems indisputable, especially in patients with septic shock. Kumar et al. [9] reported that patients with septic shock attributed to Candida infection were more likely to have a greater than 12-h delay in the initiation of effective antimicrobial therapy compared to septic shock attributed to bacterial etiologies (74.7 vs. 26.3 %) accounting, in large part, for the greater mortality associated with septic shock attributed to Candida infection (82.5 vs. 52.3 %).
The changing outcomes associated with septic shock are illustrated by a recent report from Australia and New Zealand suggesting that the mortality of septic shock has decreased over the past 10-15 years as a result of improved supportive care [10] . This is consistent with the findings from the ProCESS trial reporting one of the lowest observed mortality rates for septic shock in their control arm at 18.9 % [11]. Yet over the same time period, the mortality of septic shock attributed to Candida remained around 50 % in both the European and St. Louis studies [1, 2]. Potential explanations for this discrepancy include greater severity of illness, co-morbidities, and immune compromise among patients developing infection with Candida species. Unfortunately, these are issues the clinician is unable to modify. In contrast, delays in the administration of adequate antifungal therapy and source control are two processes of care that are potentially modifiable.
The use of antifungals, especially echinocandins, as part of empirical antimicrobial therapy in patients with septic shock is a matter of great concern to intensivists trying to balance the trade-offs between unnecessary treatment and delaying appropriate antifungals. It is worth noting that just like in the Bassetti et al.
[1] study, most reports showed that only the minority of patients (i.e., \40 %) are already receiving antifungal agents before blood culture positivity is known [2-4]. The so-called Fongiday French survey demonstrated that most of the antifungals started in the ICU were given to the wrong patients [12] . Moreover, several studies aimed at evaluating prophylactic or empirical antifungal therapy strategies in selected high-risk patients according to ''rough'' clinical criteria (i.e., previous exposure to antibiotics, sustained ICU stay, mechanical ventilation) failed to demonstrate any clinical advantage with such approaches, illustrating our current inability to administrate the right drug to the right patient [13, 14] .
Although we do not yet have clear answers as to the best approach for optimizing the administration of antifungal therapy and source control, the adverse consequences associated with delayed therapy of severe sepsis/septic shock complicating candidemia have resulted in the development of innovative diagnostic and therapeutic approaches. Tissot et al. [15] recently evaluated several strategies for the empiric treatment of lifethreatening intra-abdominal candidiasis (IAC) in highrisk surgical ICU patients. They found that 1,3-b-D-glucan antigenemia was superior to the use of the Candida score and colonization indexes for the diagnosis of blood culture-negative IAC and to direct antifungal therapy in this high-risk surgical ICU population. Alternatively, novel rapid diagnostic platforms are being developed that hold the promise for swift and accurate diagnosis of Candida bloodstream infection, potentially obviating the need for microbiologically undirected empiric therapy [16] . However, such diagnostic techniques are likely years from being universally available, suggesting that an empiric or preemptive treatment approach in patients with septic shock at high risk of Candida infection may be reasonable at the present time. Moreover, further studies are needed to prospectively assess the clinical relevance of such strategies, especially in the ''medical'' patient population whose mortality could be even worse in the setting of delayed treatment of candidemia, as source control-a key issue in their management-often cannot be achieved in most of these patients in which yeast translocation into the bloodstream is due to gut failure.
For patients whose septic shock could be attributed to Candida, on the basis of the source of infection (intraabdominal or catheter) and underlying risk factors (known Candida colonization, total parenteral nutrition, prolonged antibiotic exposure, upper digestive tract surgery), especially in healthcare-associated infections, empiric antifungal therapy seems reasonable as long as it is associated with a de-escalation of antifungal treatment based on negative microbiology results. In the future, rapid and accurate molecular diagnostic methods may become available to more accurately guide our management of septic shock in order to minimize the administration of inadequate antimicrobial therapy and to avoid unnecessary antimicrobial exposure (Fig. 1) .
